P1465: INITIAL SAFETY AND EFFICACY STUDY OF RM-001, AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS, IN TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA

• L. Wang,
• H. Xu,
• J. Liang,
• Y. Li,
• L. Shi,
• B. Xiao,
• J. Huang,
• X. Xu,
• X. Zhang

Affiliations

L. Wang

1 Department of Pediatrics, 923rd Hospital of the People’s Liberation Army, Nanning

H. Xu

2 Reforgene Medicine

J. Liang

2 Reforgene Medicine

Y. Li

1 Department of Pediatrics, 923rd Hospital of the People’s Liberation Army, Nanning

L. Shi

2 Reforgene Medicine

B. Xiao

1 Department of Pediatrics, 923rd Hospital of the People’s Liberation Army, Nanning

J. Huang

3 School of Life Sciences, Sun Yat-sen University

X. Xu

4 Department of Medical Genetics, School of Basic Medical Sciences, Southern Medical University, Guangzhou

X. Zhang

5 Department of Hematology, 923rd Hospital of the People’s Liberation Army, Nanning, China